Fisons de México, S.A. de C.V.

Fisons anticipates FDA and British health authority inspections of Opticrom and Imferon facilities in Holmes Chapel by March, paving the way for U.S. reintroduction. Tilade inhaler approval expected soon. Chairman and CEO John Kerridge resigned due to health issues, succeeded by Patrick Egan. Fisons profits declined due to U.S. market absence of Opticrom and Imferon.